拉莫三嗪(Lamotrigine) - 药物靶点：Sodium channels_在研适应症：失神发作，全身性癫痫，躁郁症1型_专利_临床

概要

基本信息

简介拉莫三嗪是一种抗惊厥药物，于1994年12月27日首次被美国食品和药品管理局批准上市。由制药公司葛兰素史克开发的，主要用于治疗Lennox Gastaut综合征、癫痫和双相情感障碍等疾病。拉莫三嗪的作用机制是通过阻断大脑中的钠通道，以稳定神经元的电活动，减轻癫痫发作的严重程度和频率。此外，拉莫三嗪还被用于治疗双相情感障碍的抑郁症状。该药物已被证明对减少癫痫发作的频率和改善患者生活质量具有显著疗效。

药物类型

小分子化药

别名

3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine、Lamotrigine (JAN/USP/INN)、430-C-78

+ [14]

靶点

Sodium channels

作用方式

阻滞剂

作用机制

钠通道阻滞剂

治疗领域

神经系统疾病遗传病与畸形其他疾病+ [2]

在研适应症

失神发作全身性癫痫躁郁症1型+ [6]

非在研适应症

暴食症抑郁症难治性抑郁症+ [9]

原研机构

GSK Plc

在研机构

GlaxoSmithKline KK上海奥科远制药有限公司

GlaxoSmithKline Export Ltd.

+ [4]

非在研机构

北京科信必成医药科技发展有限公司

葛兰素史克（中国）投资有限公司GlaxoSmithKline Pharmaceuticals SA

+ [3]

权益机构

Neuraxpharm Polska Sp zoo

Eversana Life Science Services LLC

OWP Pharmaceuticals, Inc.

+ [5]

最高研发阶段批准上市

首次获批日期

(1990-01-01),

躁郁症

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C9H7Cl2N5

InChIKeyPYZRQGJRPPTADH-UHFFFAOYSA-N

CAS号84057-84-1

关联

235

项与拉莫三嗪相关的临床试验

NCT07140913

/ Recruiting临床3期

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

开始日期2025-10-08

申办/合作机构

Bristol Myers Squibb Co.

NCT06929273

/ Recruiting临床3期

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I)
The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

开始日期2025-07-18

申办/合作机构

Bristol Myers Squibb Co.

CTR20252056

/ CompletedN/A

拉莫三嗪分散片的生物等效性试验（空腹用药试验）

主要试验目的：在健康受试者体内，在空腹条件下，以The Wellcome Foundation Limited持有的拉莫三嗪分散片（规格：50 mg，商品名：利必通®）为参比制剂，研究河北龙海药业有限公司研制的拉莫三嗪分散片（规格：50 mg；受试制剂）的药代动力学，评价受试制剂与参比制剂是否具有生物等效性。次要试验目的：观察健康受试者空腹口服受试制剂、参比制剂的安全性。

开始日期2025-06-04

申办/合作机构

河北龙海药业有限公司

100 项与拉莫三嗪相关的临床结果

登录后查看更多信息

100 项与拉莫三嗪相关的转化医学

登录后查看更多信息

100 项与拉莫三嗪相关的专利（医药）

登录后查看更多信息

9,200

项与拉莫三嗪相关的文献（医药）

2026-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Design, synthesis, and computational evaluation of ester prodrugs of isoguvacine as potential antiseizure medications

Article

作者: Maharani, Rani ; Sarian, Murni Nazira ; Feroz, Shevin Rizal ; Bakar, Khairul Azreena ; Ng, Yan Hong ; Supratman, Unang ; Lam, Su Datt ; Latip, Jalifah ; Muhajir, Muhamad Imam

Epilepsy, a neurological disorder affecting millions worldwide, has driven the development of various antiseizure medications (ASMs). Isoguvacine (IGV), a potent and selective agonist of the GABA_A receptor (GABA_AR), has shown potential in the treatment of epilepsy and other neurological disorders. However, its low blood-brain barrier permeability impairs its ability to act effectively within the central nervous system. To address this limitation, two novel ester derivatives of IGV, E7 and E14, were synthesized via Steglich esterification and evaluated through an integrated computational framework comprising density functional theory (DFT) calculations, molecular docking, molecular dynamics (MD) simulations, and in silico ADMET predictions. DFT analysis revealed that esterification significantly modified the electronic properties of IGV, with E14 exhibiting the highest polarizability (225.895 Å³) and smallest energy gap (-0.155 eV), indicative of enhanced reactivity. Molecular docking demonstrated that GABA (-8.46 kcal/mol) and IGV (-8.35 kcal/mol) exhibit similar binding affinity and complex stability with GABA_AR, supporting the reliability of our computational approach. MD simulations further confirmed the stability of these complexes, where lower RMSD, RMSF, and Rg values indicated that binding of GABA and IGV did not induce significant conformational changes in the overall receptor structure. Moreover, the derivatives were projected to exhibit optimal intestinal absorption (>90%), oral bioavailability, as well as favorable safety profiles with minimal interaction risks and non-carcinogenic properties. Collectively, these in silico findings highlight the potential of ester prodrug design to overcome the central pharmacokinetic limitations of IGV, with E14 emerging as the most promising ASM candidate for further experimental development in epilepsy therapy. Beyond identifying therapeutic advantages of E14, this study also underscores the broader value of integrated computational approaches as powerful and predictive tools in early-stage drug discovery for neurological disorders.

2025-12-31·Journal of Maternal-Fetal & Neonatal Medicine

A 10-year review of periconceptual folic acid supplementation in women with epilepsy taking antiseizure medications

Article

作者: O’Higgins, Amy ; McIntosh, Trudi ; Turner, Ciara ; Gaffney, Damon ; Hogan, Jennifer ; Germaine, Mark

BACKGROUND:

Epidemiological studies have reported that women with epilepsy who are taking antiseizure medications have an increased risk of Neural Tube Defects. Periconceptual folic acid supplementation potentially prevents two-thirds of cases. International guidelines recommend that women at increased risk of a pregnancy complicated by a Neural Tube Defect who could become pregnant should start high-dose (5 mg daily) oral folic acid at least three months before conceiving. The purpose of the study was to examine supplementation in women taking antiseizure medications who delivered a baby weighing >499 g during the ten years 2013-2022 in a large maternity hospital.

METHODS:

The hospital's computerized database contains standardized maternal clinical and sociodemographic details which were entered at the first antenatal visit in the obstetric records. The data on all women with epilepsy taking antiseizure medications was anonymized before coding.

RESULTS:

In the ten years, 75,869 women delivered a baby weighing >499 g. Of the deliveries, 632 (0.83%) were to women with epilepsy. Of these, 250 (0.33%) were taking antiseizure medications when they presented for antenatal care. The most frequently prescribed medications were lamotrigine n = 98 (33.8%) and levetiracetam n = 89 (30.7%). Monotherapy was prescribed in 211 (84.4%) women and polytherapy in 39 (15.6%). Three (1.2%) women took no folic acid before or after conception and 59 (23.6%) only took it after conception. Of the 188 (75.2%) who took folic acid before conception, 164 (65.6%) took high-dose 5 mg and 24 (9.6%) took low-dose 0.4 mg. No maternal characteristics were associated with taking high-dose folic acid before conception. Compliance with the national guidelines in the 16 women taking valproate was 30.8% compared with 76.0% for the other 234 women taking medications (p < 0.03). Compliance in the 211 women receiving monotherapy was 72.5% compared with 25.6% in the 39 women receiving polytherapy (p < 0.03).

CONCLUSIONS:

Two-thirds of women taking antiseizure medications complied with national guidelines on high-dose periconceptual folic acid supplementation. A particular concern is the suboptimal compliance in women prescribed valproate and polytherapy, which are two cohorts at higher risk of a neural tube defect. These findings need to be communicated to women with epilepsy in their reproductive years and their doctors.

KEY POINTS:

Of 75,869 women delivered over 10 years, 250 (0.33%) were on medications for epilepsy at presentation34.4% of women taking medications did not start high dose folic acid before conception23.6% of women did not start folic acid until after conceptionCompliance with recommendations was lowest in women prescribed valproate or polytherapyNo maternal characteristics were identified which were associated with suboptimal compliance.

2025-12-31·DRUG DELIVERY

Development, in vitro and ex vivo characterization of lamotrigine-loaded bovine serum albumin nanoparticles using QbD approach

Article

作者: Kiricsi, Ágnes ; Zupkó, István ; Szalenkó-Tőkés, Ágnes ; Csóka, Ildikó ; Rovó, László ; Schelz, Zsuzsanna ; Salamah, Maryana ; Balogh, György Tibor ; Katona, Gábor ; Sipos, Bence

The present study aimed to prepare and optimize lamotrigine-loaded bovine serum albumin nanoparticles (LAM-NP) using the Quality by Design (QbD) approach and to investigate both the in vitro and ex vivo effects of different cross-linking agents glutaraldehyde (GLUT), glucose (GLUC) and 1-(3-dimethylaminutesopropyl)-3-ethylcarbodiimide hydrochloride (EDC) on intranasal applicability. Cross-linked LAM-NP from EDC (NP-EDC-1) showed the lowest Z-average value (163.7 ± 1.9 nm) and drug encapsulation efficacy (EE%) of 97.31 ± 0.17%. The drug release of GLUC cross-linked LAM-NP (NP-GLUC-9), glutaraldehyde cross-linked LAM-NP (NP-GLUT-2), and NP-EDC-1 at blood circulation conditions was higher than the initial LAM. The results of the blood-brain barrier parallel artificial membrane permeability assay (BBB-PAMPA) showed an increase in the permeability of LAM through the BBB with NP-GLUC-9 and an increase in flux with all selected formulations. The ex vivo study showed that LAM diffusion from the selected formulations through the human nasal mucosa was higher than in case of initial LAM. The cytotoxicity study indicated that BSA-NP reduced LAM toxicity, and GLUC 9 mM and EDC 1 mg could be alternative cross-linking agents to avoid GLUT 2% v/v toxicity. Furthermore, permeability through Caco-2 cells showed that nasal epithelial transport/absorption of LAM was improved by using BSA-NPs. The use of BSA-NP may be a promising approach to enhance the solubility, permeability through BBB and decrease the frequency of dosing and adverse effects of LAM.

130

项与拉莫三嗪相关的新闻（医药）

2025-10-23

·PRNewswire

OWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral Suspension

Novel therapy for epilepsy and bipolar disorders received FDA approval in September CHICAGO, Oct. 23, 2025 /PRNewswire/ -- OWP Pharmaceuticals, a privately held, commercial-stage neuroscience specialty pharmaceutical company, today announced that EVERSANA®, a leading provider of commercialization services to the global life sciences industry, will provide U.S. commercialization services for the launch of SUBVENITE® (lamotrigine) oral suspension, the company's novel treatment for epilepsy and bipolar disorders. SUBVENITE®, approved by the U.S. Food and Drug Administration on September 16, 2025, is the first and only FDA-approved lamotrigine oral suspension in the U.S. It is designed to help improve access to epilepsy treatments as a flexible, patient-friendly alternative to tablets. Lamotrigine is widely prescribed, but is now available in a ready-to-use liquid version. SUBVENITE® Oral Suspension is ideal for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations. To support a successful product launch, EVERSANA is currently activating an array of services, including field deployment, data & analytics, and co-pay services. The SUBVENITE® launch support is part of EVERSANA and OWP's broader commercialization partnership announced in January 2022. "Market access challenges continue to be the major hurdle for patients looking for new treatment options," said Gregory Skalicky, President, EVERSANA. "Together with OWP Pharmaceuticals, we're removing barriers and helping patients find new hope." OWP Pharmaceutical's commitment to innovation for patients expands beyond the United States. Since its founding in 2014, the company has developed a unique partnership with the ROW Foundation to support humanitarian efforts for people worldwide with epilepsy. As innovative new solutions like SUBVENITE become available, OWP is committed to ensuring it reaches patients in need, as nearly 80% of people with epilepsy live in underdeveloped countries, and about 75% of them do not have access to a treatment option. "Working with EVERSANA to support commercialization efforts in the U.S. is an important milestone for patients," said Scott Boyer, Founder and President, OWP Pharmaceuticals. "But our vision continues to be much larger, that every epilepsy patient globally one day might have access through OWP Pharma and ROW Foundation, the Pharmaceutical Social Enterprise®. To learn more about OWP Pharmaceuticals, visit . About EVERSANA EVERSANA® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X. About OWP Pharmaceuticals OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. Based in Lisle, IL, OWP is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide. Media Contacts For EVERSANA Matt Braun Vice President, Corporate Communications [email protected] For OWP [email protected] SOURCE EVERSANA; OWP Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-09-17

·EINPresswire

OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® Oral Suspension

The First and Only Lamotrigine Oral Suspension in the U.S. LISLE, IL, UNITED STATES, September 17, 2025 / EINPresswire.com / -- OWP Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved SUBVENITE ® Oral Suspension, the first and only lamotrigine oral suspension in the United States. This innovative formulation will offer treatment options for patients and healthcare providers by offering a flexible, patient-friendly alternative to tablets. Lamotrigine is widely prescribed, but until now only solid oral dosage forms have been available. SUBVENITE ® Oral Suspension is designed for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations. “The FDA approval of SUBVENITE ® Oral Suspension — the first and only lamotrigine oral suspension — represents a significant advancement in patient care,” said Scott Boyer, Founder and President, OWP Pharmaceuticals. “We are proud to bring this much needed treatment option to patients and clinicians, with availability anticipated later in 2025.” Key Features and Benefits of SUBVENITE ® Oral Suspension: - First and only FDA-approved lamotrigine oral suspension in the U.S. - Improved accessibility: Suitable for patients with swallowing challenges, those requiring individualized dosing, or those who prefer liquid medication formulations. - Precision dosing: Liquid formulation allows for dose titration and flexibility. - Therapeutic reliability: Developed to deliver the expected safety and efficacy profile as lamotrigine tablets (1). Availability SUBVENITE ® Oral Suspension has been FDA-approved and is expected to be available in the United States later in 2025 through leading distribution channels. Full prescribing information is available at www.owppharma.com . SUBVENITE is indicated for (2): Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures • primary generalized tonic-clonic (PGTC) seizures • generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients aged 16 years and older: •Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. Bipolar disorder: •Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. About OWP Pharmaceuticals OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. Based in Chicago, OWP is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide. Media Contact: info@owppharma.com References: 1. DOF: Data on File. OWP Pharmaceuticals, Inc. 2. SUBVENITE ® Oral Suspension [package insert]. Lisle, IL: OWP Pharmaceuticals, Inc.; 2025. info@owppharma.com OWP Pharmaceuticals info@owppharma.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-09-17

·FiercePharma

SK's blockbuster hopeful Xcopri reduces seizures in phase 3 trial, teeing up FDA expansion bid

SK Biopharmaceutical hopes to cross the $1 billion sales marker for Xcopri by 2029. SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of building a blockbuster with an expansion into another seizures subtype.The South Korean pharma won FDA approval for Xcopri in 2019 as a treatment for partial-onset seizures, also known as focal seizures, in adults. Since then, with rapid global growth, SK has outlined blockbuster ambitions for the drug by 2029. Now, with a positive phase 3 trial, another indication for primary generalized tonic-clonic (PGTC) seizures could be on the table. In its phase 3 study, SK evaluated Xcopri in 169 adult and adolescent patients with PGTC seizures, finding a “statistically significant reduction” in the seizures, the company said in a filing on the Korea Exchange. Specifically, seizure frequency from baseline levels was reduced by 71.9% in the Xcopri-treated group and 39.6% in the placebo arm over 28-day intervals.PGTC seizures are the most common type of generalized seizures—which are less prevalent than focal seizures—and considered the most severe due to the high risk of seizure-related injury and sudden unexpected death in epilepsy, SK pointed out. With limited treatment options, the company hopes Xcopri can address an unmet need and contribute to quality-of-life improvements for epilepsy patients, it said.While the current treatment landscape for the seizure type is sparse and generally made up of antiseizure medications such as GSK’s off-patent Lamictal, SK isn’t the only one looking to edge in on the market. Xenon Pharmaceuticals is approaching an early 2026 phase 3 readout of its lead candidate, azetukalner, in focal seizures as an additional phase 3 trial in PGTC seizures continues.According to a note by Jefferies analysts, SK’s win in PGTC seizures “serves as a reminder” that Xenon’s azetukalner could show “broad-spectrum activity” as well, supporting peak sales expectations of $400 million from that indication alone and $1 billion on the focal seizures side. However, SK still has some breathing room from the competition as the analysts note that SK’s study took seven years to produce top-line data after its 2018 start, suggesting that Xenon’s phase 3 could take “several years” as well.SK will file for a label expansion with the FDA and present additional analysis from the study at the American Epilepsy Society Annual Meeting in December. Last quarter, Xcopri helped the company reach record sales with U.S. revenues of $111 million.

临床3期上市批准临床结果

100 项与拉莫三嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00354	拉莫三嗪	N03AX09	DB00555

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
失神发作	日本	GlaxoSmithKline KK	2015-09-24
全身性癫痫	日本	GlaxoSmithKline KK	2008-10-16
躁郁症1型	美国	GlaxoSmithKline LLC	2003-06-20
癫痫部分性发作	美国	GlaxoSmithKline LLC	1998-08-24
强直阵挛性癫痫	中国	GlaxoSmithKline Export Ltd.	1996-07-02
Lennox-Gastaut综合征	美国	GlaxoSmithKline LLC	1994-12-27
癫痫发作	美国	GlaxoSmithKline LLC	1994-12-27
躁郁症	-	GSK Plc	1990-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
抑郁症	临床3期	中国	葛兰素史克（中国）投资有限公司	2012-08-21
抑郁症	临床3期	中国	GlaxoSmithKline Pharmaceuticals SA	2012-08-21
抑郁症	临床3期	中国	GlaxoSmithKline Export Ltd.	2012-08-21
暴食症	临床3期	美国	GSK Plc	2006-03-01
肥胖	临床3期	美国	GSK Plc	2006-03-01
癫痫	临床3期	美国	GSK Plc	2005-10-01
疱疹后神经痛	临床3期	美国	GSK Plc	2005-02-01
精神分裂症	临床3期	美国	GSK Plc	2003-08-01
躁狂	临床3期	荷兰	GSK Plc	2002-08-01
躁狂	临床3期	西班牙	GSK Plc	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


FDA_CDER 人工标引	N/A	躁郁症	575	lamotrigine 50 mg/day (Trial 1)	繭鹹夢鬱觸窪齋餘糧壓(鏇鬱鬱選壓鏇鹹淵構糧) = superior to placebo in delaying the time to occurrence of a mood episode 廠鹽鹽構糧膚壓鑰壓鹹 (壓衊獵齋範製觸蓋鏇窪 )	积极	2025-09-16
				lamotrigine 200 mg/day (Trial 1)
FDA_CDER 人工标引	N/A	Lennox-Gastaut综合征	169	Lamotrigine	餘餘壓壓夢積廠顧糧鹽(鬱遞願願觸願襯襯鹽願) = 齋顧選遞構鏇淵網願鏇醖鑰廠鏇構鹹鏇積糧選 (鑰窪製簾壓鬱築築憲醖 )	积极	2025-09-16
				Placebo	餘餘壓壓夢積廠顧糧鹽(鬱遞願願觸願襯襯鹽願) = 繭鹽衊遞襯鹽鹹鹽鏇糧醖鑰廠鏇構鹹鏇積糧選 (鑰窪製簾壓鬱築築憲醖 )
FDA_CDER 人工标引	N/A	强直阵挛性癫痫	117	Lamotrigine	遞夢餘構觸鑰廠簾築鑰(鬱淵艱糧壓鏇鹽壓衊餘) = 鑰繭鹽觸簾壓鬱鏇壓憲網選壓膚鑰繭窪夢憲製 (糧糧窪衊淵鑰憲鏇遞顧 )	积极	2025-09-16
				Placebo	遞夢餘構觸鑰廠簾築鑰(鬱淵艱糧壓鏇鹽壓衊餘) = 壓衊醖齋憲壓願襯獵積網選壓膚鑰繭窪夢憲製 (糧糧窪衊淵鑰憲鏇遞顧 )
FDA_CDER 人工标引	N/A	癫痫部分性发作	355	Lamotrigine 300 mg/day (One trial)	膚窪鬱淵糧鑰網積顧積(繭淵窪願遞積鑰顧願鬱) = 襯鬱壓繭製願蓋願製廠鹽醖淵選鹹製築艱範蓋 (憲壓衊膚鏇窪築願範糧 ) 更多	积极	2025-09-16
				Lamotrigine 500 mg/day (One trial)	膚窪鬱淵糧鑰網積顧積(繭淵窪願遞積鑰顧願鬱) = 範鏇鹹築壓夢繭糧膚築鹽醖淵選鹹製築艱範蓋 (憲壓衊膚鏇窪築願範糧 ) 更多
FDA_CDER 人工标引	N/A	癫痫部分性发作	156	Lamotrigine 500 mg/day	遞窪鹹構醖憲襯餘簾襯(襯繭鑰艱鬱壓艱壓簾襯) = 製襯夢艱獵顧淵鑰淵鹽製遞艱廠淵繭餘膚蓋衊 (齋選簾壓憲憲製鬱齋夢 ) 达到	积极	2025-09-16
				Valproate 1,000 mg/day	遞窪鹹構醖憲襯餘簾襯(襯繭鑰艱鬱壓艱壓簾襯) = 範製鹹觸範觸簾選顧願製遞艱廠淵繭餘膚蓋衊 (齋選簾壓憲憲製鬱齋夢 ) 达到
FDA_CDER 人工标引	N/A	癫痫部分性发作	199	Lamotrigine	鹽餘夢糧夢壓願膚獵壓(網構選製簾憲鬱鏇網簾) = 構齋選醖艱夢構淵網製廠鏇獵襯製艱餘繭鹹鏇 (範鹹艱範遞艱繭範鹹繭 )	积极	2025-09-16
				Placebo	鹽餘夢糧夢壓願膚獵壓(網構選製簾憲鬱鏇網簾) = 憲襯壓簾遞選壓積鹹構廠鏇獵襯製艱餘繭鹹鏇 (範鹹艱範遞艱繭範鹹繭 )
NCT03689114 (STANDLOW, CTgov)	临床4期	癫痫部分性发作	58	Low dose oxcarbazepine+Low dose topiramate+Low dose carbamazepine+Low dose levetiracetam+Low dose valproate+Low dose lamotrigine+Low dose zonisamide+Low dose gabapentin (Low Dose)	鹹獵簾壓壓獵襯壓齋夢 = 獵窪觸窪製廠窪壓鹹繭窪獵選鹹鹹網衊選蓋膚 (醖願製築獵鬱繭構鹹鏇, 選夢蓋艱艱膚鏇製襯顧 ~ 積鬱網窪顧製築鹹醖鹹) 更多	-	2025-07-08
				oxcarbazepine+topiramate+carbamazepine+levetiracetam+valproate+lamotrigine+gabapentin+zonisamide (Standard Dose)	鹹獵簾壓壓獵襯壓齋夢 = 廠製製鏇鹹餘窪積觸蓋窪獵選鹹鹹網衊選蓋膚 (醖願製築獵鬱繭構鹹鏇, 選築糧艱鹹夢蓋鑰繭衊 ~ 艱艱鬱廠鏇遞鏇觸糧鹽) 更多
NCT04770493 (CTgov)	临床2期	酒精使用障碍	44	Lamotrigine (Lamotrigine)	夢構蓋鏇築遞簾憲鬱夢 = 選鹽選製積願鑰觸糧顧醖選艱構蓋遞窪夢築淵 (繭鏇鑰網淵鹽鏇觸遞獵, 鑰簾鬱淵膚觸鬱範鏇選 ~ 製蓋夢鑰鹽獵選醖觸簾) 更多	-	2025-06-13
				Placebo (Placebo)	夢構蓋鏇築遞簾憲鬱夢 = 願製餘範觸積醖鬱繭獵醖選艱構蓋遞窪夢築淵 (繭鏇鑰網淵鹽鏇觸遞獵, 膚鏇餘獵築糧餘鏇廠觸 ~ 築積鹽選鑰鑰憲鹹夢醖) 更多
P9-9.015 (AAN2025)	N/A	白天过度嗜睡	207	Clonazepam	憲鹹糧襯遞蓋範壓構簾(壓願餘餘衊鏇壓鹹選襯) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 觸憲膚積廠製襯築獵願 (壓蓋遞觸艱繭淵鑰網遞 )	积极	2025-04-07
				Levetiracetam
CRD42022363844 (AAN2024)	N/A	癫痫发作	18,676	Phenytoin	製網糧窪顧餘顧壓鬱觸(廠構簾餘鬱淵齋獵醖鬱) = 鑰選簾糧製範築選鹹築選網構觸觸醖繭築顧製 (願淵襯獵蓋顧鑰築網餘, 23.2–52.8)	积极	2024-04-09
				Carbamazepine	製網糧窪顧餘顧壓鬱觸(廠構簾餘鬱淵齋獵醖鬱) = 壓壓夢鏇糧壓糧襯膚餘選網構觸觸醖繭築顧製 (願淵襯獵蓋顧鑰築網餘, 1.7–5.3)